The relationship between early changes in the HAMD-17 anxiety/somatization factor items and treatment outcome among depressed outpatients

International Clinical Psychopharmacology

Volumn 20, Issue 2, 2005, Pages 87-91

  Farabaugh, Amy ^a   Mischoulon, David ^a   Fava, Maurizio ^a   Wu, Shirley L ^a   Mascarini, Alessandra ^a   Tossani, Eliana ^a   Alpert, Jonathan E ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Depression; Hamilton Rating Scale for Depression (HAMD 17); Treatment outcome

Indexed keywords

FLUOXETINE; HYPERICUM PERFORATUM EXTRACT;

ADULT; ANXIETY; ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; FATIGUE; FEMALE; HAMILTON SCALE; HUMAN; INTERVIEW; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; OUTPATIENT; PREDICTION; PRIORITY JOURNAL; REMISSION; SCORING SYSTEM; SOMATIZATION; STRUCTURED CLINICAL INTERVIEW FOR DSM IV; SYMPTOM; TREATMENT OUTCOME; UNITED STATES;

ADOLESCENT; ADULT; AGED; ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANXIETY; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; FEMALE; FLUOXETINE; HUMANS; HYPERICUM; MALE; MIDDLE AGED; PLANT EXTRACTS; PSYCHIATRIC STATUS RATING SCALES; SOMATOFORM DISORDERS; TREATMENT OUTCOME;

EID: 14844352158     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-200503000-00004     Document Type: Article

References (19)

1. Bech P (2001). Meta-analysis of placebo-controlled trials with mirtazapine using the core items of the Hamilton Depression Scale as evidence of a pure antidepressive effect in the short-term treatment of major depression. Int J Neuropsychopharmacol 4:337-345.
2. Cook IA, Leuchter AF (2001). Prefrontal changes and treatment response prediction in depression. Semin Clin Neuropsychiatry 6:113-120.
3. Dunner DL, Goldstein DJ, Mallinckrodt C, Lu Y, Detke MJ (2003). Duloxetine in treatment of anxiety symptoms associated with depression. Depress Anxiety 18:53-61.
4. Fava M, Davidson KG (1996). Definition and epidemiology of treatment-resistant depression. Psychiatry Clin North Am 19:179-200.
5. Fava M, Rosenbaum JF, Hoog SL, Tepner RG, Kopp JB, Nilsson ME (2000). Fluoxetine versus sertraline and paroxetine in major depression: tolerability and efficacy in anxious depression. J Affect Disord 59:119-126.
6. Fava M, Alpert JE, Nierenberg AA, Mischoulon D, Otto MW, Zajecka J, et al. (2004). A double-blinded, randomized trial of St John's Wort, fluoxetine, and placebo in major depressive disorder. J Clin Psychopharmacol in press.
7. First MB, Spitzer RL, Gibbon M, Williams JBW (1996). Structured Clinical Interview for the DSM-IV Axis I Disorders - Patient edn. New York, New York: Biometrics Research Department, New York State Psychiatric Institute.
8. Hamilton M (1960). A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56-62.
9. Katz MM, Tekell JL, Bowden CL, Brannan S, Houston JP, Berman N, Frazer A (2004). Onset and early behavioral effects of pharmacologically different antidepressants and placebo in depression. Neuropsychopharmacology 29:566-579.
10. Nierenberg AA, Pava JA, Clancy K, Rosenbaum JF, Fava M (1996). Are neurovegetative symptoms stable in relapsing or recurrent atypical depressive episodes. Biol Psychiatry 40:691-696.
11. Nierenberg AA, Farabaugh AH, Alpert JE, Gordon J, Worthington JJ, Rosenbaum JF, Fava M (2000). Timing of onset of antidepressant response with fluoxetine treatment. Am J Psychiatry 157:1423-1428.
12. Quitkin FM, Rabkin JG, Ross D, Stewart JW (1984). Identification of true drug response to antidepressants. Arch Gen Psychiatry 41:782-786.
13. Quitkin FM, Petkova E, McGrath PJ, Taylor B, Beasley C, Stewart J, et al. (2003). When should a trial of fluoxetine for major depression be declared failed? Am J Psychiatry 160:734-740.
14. Sonawalla SB, Farabaugh A, Johnson MW, Morray M, Delgado ML, Pingol MG, et al. (2002). Fluoxetine treatment of depressed patients with comorbid anxiety disorders. J Psychopharmacol 16:215-219.
15. Stassen HH, Delini-Stula A, Angst J (1993). Time course of improvement under antidepressant treatment: a survival analytical approach. Eur Neuropsychopharmacol 3:127-135.
16. Stassen HH, Angst J, Delini-Stula A (1994). Severity at baseline and onset of improvement in depression: meta-analysis of imipramine and moclobemide versus placebo. Eur Neuropsychopharmacol 9:129-136.
17. Stewart JW, Quitkin FM, McGrath PJ, Amsterdam J, Fava M, Fawcett J, et al. (1998). Use of pattern analysis to predict differential relapse of remitted patients with major depression during 1 year of treatment with fluoxetine or placebo. Arch Gen Psychiatry 55:334-343.
18. Szegedi A, Muller MJ, Anghelescu I, Klawe C, Kohnen R, Benkert O (2003). Early improvement under mirtazapine and paroxetine predicts later stable response and remission with high sensitivity in patients with major depression. J Clin Psychiatry 64:413-420.
19. Tollefson GD, Holman SL (1994). How long to onset of antidepressant action: a meta-analysis of patients treated with fluoxetine or placebo. Int Clin Psychopharmacol 9:245-250.